| MeSH term | MeSH ID | Detail |
|---|---|---|
| Adenocarcinoma | D000230 | 166 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
(e,z)-farnesol
(e,z)-farnesol is a lipid of Prenol Lipids (PR) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 3613 references associated with (e,z)-farnesol in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for (e,z)-farnesol
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with (e,z)-farnesol
PubChem Biomolecular Interactions and Pathways
All references with (e,z)-farnesol
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Lutz RJ et al. | Nucleoplasmic localization of prelamin A: implications for prenylation-dependent lamin A assembly into the nuclear lamina. | 1992 | Proc. Natl. Acad. Sci. U.S.A. | pmid:1557405 |
| Kotti T et al. | Biphasic requirement for geranylgeraniol in hippocampal long-term potentiation. | 2008 | Proc. Natl. Acad. Sci. U.S.A. | pmid:18685105 |
| Jackson JH et al. | Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. | 1990 | Proc. Natl. Acad. Sci. U.S.A. | pmid:2183224 |
| Caldwell GA et al. | Consequences of altered isoprenylation targets on a-factor export and bioactivity. | 1994 | Proc. Natl. Acad. Sci. U.S.A. | pmid:8108401 |
| Laezza C et al. | v-K-ras leads to preferential farnesylation of p21(ras) in FRTL-5 cells: multiple interference with the isoprenoid pathway. | 1998 | Proc. Natl. Acad. Sci. U.S.A. | pmid:9811854 |
| Fisher JE et al. | Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. | 1999 | Proc. Natl. Acad. Sci. U.S.A. | pmid:9874784 |
| Lai RK et al. | The gamma subunit of transducin is farnesylated. | 1990 | Proc. Natl. Acad. Sci. U.S.A. | pmid:2217200 |
| Casey PJ et al. | p21ras is modified by a farnesyl isoprenoid. | 1989 | Proc. Natl. Acad. Sci. U.S.A. | pmid:2682646 |
| Stone KJ and Strominger JL | Inhibition of sterol biosynthesis by bacitracin. | 1972 | Proc. Natl. Acad. Sci. U.S.A. | pmid:4338587 |
| Lopez-Medina E et al. | Candida albicans Inhibits Pseudomonas aeruginosa Virulence through Suppression of Pyochelin and Pyoverdine Biosynthesis. | 2015 | PLoS Pathog. | pmid:26313907 |